RetiredCareFirstPolicy N/A

Transpupillary Thermotherapy (TTT)

Defines medical necessity and investigational indications for transpupillary thermotherapy (TTT) for ophthalmic conditions; affects providers submitting coverage requests to CareFirst BlueCross BlueShield.

Policy Summary

PayerCareFirst

PolicyTranspupillary Thermotherapy (TTT)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify benefits and obtain authorization when requesting TTT; it is covered only for retinoblastoma and choroidal melanoma and investigational for other indications.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2medically necessary conditions

5BCBSA/TEC items

2012-2022literature period

2014notable series year

Coverage Criteria — Transpupillary Thermotherapy (TTT)

Medically Necessary Indications

Covered when used as a treatment for the following diagnoses:

Policy Summary

PayerCareFirst

PolicyTranspupillary Thermotherapy (TTT)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify benefits and obtain authorization when requesting TTT; it is covered only for retinoblastoma and choroidal melanoma and investigational for other indications.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Experimental / Investigational Indications

Not covered / Investigational when used for other ocular conditions:

Investigational indications: Transpupillary thermotherapy (TTT) is considered experimental/investigational for all other conditions, including choroidal neovascularization due to age-related macular degeneration (AMD), central serous chorioretinopathy, polypoidal choroidal vasculopathy, circumscribed choroidal hemangioma, choroidal indeterminate melanocytic lesions, and retinal astrocytoma; available evidence does not meet TEC criteria and is insufficient to demonstrate consistent improvement in net health outcome or equivalence to established therapies (e.g., anti-VEGF intravitreal therapy or photodynamic therapy).

Evidence from randomized trials and comparative studies is limited or inconclusive; anti‑VEGF therapy is the first‑line treatment for neovascular AMD.

Transpupillary thermotherapy (TTT) for neovascular age-related macular degeneration (CNV) and other retinal conditions listed in the policy (including central serous chorioretinopathy, polypoidal choroidal vasculopathy, circumscribed choroidal hemangioma, choroidal indeterminate melanocytic lesions, and retinal astrocytoma) is considered not medically necessary / investigational. Peer-reviewed randomized trials and comparative studies have not shown consistent vision benefit or superiority to established treatments (for example, anti-VEGF intravitreal therapy), and evidence is insufficient to conclude that TTT improves net health outcomes for these indications.

Provider Actions / Billing Guidance

Prior Authorization

Prior Authorization & Coverage Stance

Prior authorization and coverage stance: Transpupillary thermotherapy (TTT) is considered medically necessary only for retinoblastoma and choroidal melanoma. Use of TTT for all other indications is considered experimental/investigational and is unlikely to be covered.

Medically necessary indications: retinoblastoma; choroidal melanoma
Investigational / not covered for other ocular conditions including AMD-related choroidal neovascularization

Note

Preferred First-Line Therapy

Preferred first-line therapy: For neovascular (wet) age-related macular degeneration (AMD), intravitreal anti-VEGF therapy (e.g., aflibercept, bevacizumab, ranibizumab) is the first-line and most effective treatment. TTT is investigational for neovascular AMD and should not be used in place of anti-VEGF therapy.

First-line: Intravitreal anti-VEGF agents (aflibercept, bevacizumab, ranibizumab)
Alternative therapies (e.g., PDT) may be considered per guidelines; TTT is not a recommended alternative for AMD

Denial Risk

Denial Risk for Non-Covered Indications

Denial risk for non-covered indications: Requests for TTT outside the covered indications (retinoblastoma and choroidal melanoma) are likely to be denied as experimental/investigational. Provide supporting clinical documentation if requesting an exception.

Non-covered examples: choroidal neovascularization due to AMD; central serous chorioretinopathy; polypoidal choroidal vasculopathy; circumscribed choroidal hemangioma; choroidal indeterminate melanocytic lesions; retinal astrocytoma
Include literature and rationale when requesting coverage exceptions

Documentation Required

Benefit Verification

Benefit verification: Coverage varies by contract and line of business. Verify member benefits and prior authorization requirements at the plan/contract level before scheduling TTT.

Confirm medical necessity criteria are met for retinoblastoma or choroidal melanoma
Obtain prior authorization when required by the member's contract

Background

Transpupillary thermotherapy (TTT) delivers focused infrared thermal energy through the dilated pupil into the posterior segment of the eye to ablate diseased tissue. It has been used as a stand-alone or adjunctive treatment (for example, combined with chemotherapy or radiation) primarily for intraocular tumors such as retinoblastoma and choroidal melanoma. Evidence for use of TTT in neovascular AMD and various non-neoplastic retinal conditions is limited, with small studies and inconsistent results that do not demonstrate clear net health benefit.

Definitions

Transpupillary thermotherapy (TTT) — definition of the procedure

Procedure definitionTranspupillary thermotherapy (TTT) delivers infrared thermal energy through the dilated pupil into the posterior segment of the eye to ablate diseased tissue, either as a stand-alone treatment or adjunctive therapy (e.g., with chemotherapy).

Energy modalityInfrared laser energy is delivered through the pupil to target intraocular tissue with the goal of ablating diseased tissue while minimizing damage to surrounding healthy tissue.

Anatomic targetPosterior segment of the eye (intraocular structures), used for conditions such as retinoblastoma and choroidal melanoma.

Therapeutic intentUsed to ablate pathological tissue and preserve vision; may be applied as primary therapy or adjunct to other modalities depending on clinical application.

Delivery characteristicsHeat is transmitted through the dilated pupil into the interior of the eye via laser to perform intraocular surgical procedures.

Experimental/Investigational assessment criteria (BCBSA/TEC)

BCBSA/TEC criteria 1The technology must have final approval from the appropriate U.S. government regulatory bodies.

BCBSA/TEC criteria 2The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.

BCBSA/TEC criteria 3The technology must improve the net health outcome.

BCBSA/TEC criteria 4The technology must be as beneficial as any established alternatives.

BCBSA/TEC criteria 5The improvement must be attainable outside the investigational settings.